Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer
Overall survival and response rates of patients are consistent with previous reports on PSMA-targeted RPT while the absence of xerostomia can be considered an improvement. Up to four cycles of [<sup>177</sup>Lu]Lu-SibuDAB were well tolerated and [<sup>177</sup>Lu]Lu-SibuDAB appears to be a valid option for effective treatment of patients with progressive mCRPC. Randomized clinical trials to assess efficacy compared to established RPT are warranted.
Authors
- Cristian Soza‐Ried
- Vasko Kramer (ORCID: https://orcid.org/0000-0002-5285-6447)
- Roberto Estay
- Heinz Nicolai (ORCID: https://orcid.org/0000-0002-1916-2291)
- Philipp Ritt
- Konstantin Zhernosekov
- Frank Fliegert
- Korbinian Krieger (ORCID: https://orcid.org/0000-0002-5649-0710)
- René Fernández (ORCID: https://orcid.org/0000-0002-0426-8536)
- Yun Qin
- Horacio Amaral (ORCID: https://orcid.org/0000-0003-1633-2125)
- Cristina Müller (ORCID: https://orcid.org/0000-0001-9357-9688)
Institutions
- Paul Scherrer Institute (CH)
- ETH Zurich (CH)
- Hospital del Salvador (CL)
- Positron Systems (United States) (US)
- Instituto Profesional Providencia (CL)
- Isotopen Technologien München (Germany) (DE)
- Hospital San Borja Arriarán (CL)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s00259-025-07634-z
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00